یکشنبه 2 دی 1403
[Archive]
دوره 31، شماره 146 - ( 4-1402 )
جلد 31 شماره 146 صفحات 243-238 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mortazavi Moghadam S G, Zarban A, Yaghobbi Marakieh R, Allahyari E. Some Beneficial Effects of Coenzyme Q10 Supplementation on Patients with Chronic Obstructive Pulmonary Disease. J Adv Med Biomed Res 2023; 31 (146) :238-243
URL: http://journal.zums.ac.ir/article-1-6854-fa.html
URL: http://journal.zums.ac.ir/article-1-6854-fa.html
Some Beneficial Effects of Coenzyme Q10 Supplementation on Patients with Chronic Obstructive Pulmonary Disease. Journal of Advances in Medical and Biomedical Research. 1402; 31 (146) :238-243
چکیده: (2779 مشاهده)
Background and Objective: Chronic inflammation, dyspnea and activity limitation are common phenomena in patients with chronic obstructive lung disease. Clinical studies suggest that Ubiquinone has anti-inflammatory and energetic properties. Here the beneficial effect of CoQ10 in patients with COPD will be studied.
Materials and Methods: Baesd on the census method, 90 patients with moderate to severe COPD were divided into two identical placebo and CoQ10 groups. High sensitive-C-reactive protein (hs-CRP), Forced Expiratory Volume in 1 second, numerical rating breathlessness scale and "the time to get exhausted" were evaluated and recorded at baseline and the end of the study. The CoQ10 group received 120 mg of CoQ10 supplement per day versus the placebo group who also received a placebo (identical in look, size and taste to pharmaceutical sample) and were followed for 6 weeks. Data were analyzed using t-test, and nonparametric statistical tests. Qualitative variables were assessed by chi-square or Fisher exact tests.
Results: The study included 49(53.6%) women and 41(46.4%) men, collectively 90 patients with moderate to severe COPD. The mean age was 66.97±12.59 years in the placebo and 64.21±11.78 years in the CoQ10 group (p=0.30). Breathlessness scale was improved in CoQ10 group (p<0.001). hs-CRP significantly declined after intervention in the CoQ10 compared to the placebo group (p<0.001).No serious side effects were observed as a result of CoQ10 consumption.
Conclusion: Daily administration of CoQ10 in COPD patients increases hs-CRP and improves dyspnea and "the time to get exhausted” without side effect.
نوع مطالعه: مقاله پژوهشی |
موضوع مقاله:
Clinical medicine
دریافت: 1401/4/24 | پذیرش: 1401/11/29 | انتشار: 1402/4/5
دریافت: 1401/4/24 | پذیرش: 1401/11/29 | انتشار: 1402/4/5
فهرست منابع
1. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):26-33. [DOI:10.1513/pats.200408-039MS] [PMID]
2. Zhai J, Bo Y, Lu Y, Liu C, Zhang L. Effects of coenzyme Q10 on markers of inflammation: A systematic review and meta-analysis. PLoS One. 2017;12(1):e0170172. [DOI:10.1371/journal.pone.0170172] [PMID] [PMCID]
3. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J. 2007;16(4):236-40. [DOI:10.3132/pcrj.2007.00047] [PMID] [PMCID]
4. Quinzii CM, DiMauro S, Hirano M. Human coenzyme Q10 deficiency. Neurochem Res. 2007;32(4-5):723-27. [DOI:10.1007/s11064-006-9190-z] [PMID] [PMCID]
5. Alehagen U, Alexander J, Aaseth J, Larsson A. Decrease in inflammatory biomarker concentration by intervention with selenium and coenzyme Q10: a subanalysis of osteopontin, osteoprotergerin, TNFr1, TNFr2 and TWEAK. J Inflamm (Lond). 2019;16:5. [DOI:10.1186/s12950-019-0210-6] [PMID] [PMCID]
6. Saini R. Coenzyme Q10: The essential nutrient. J Pharm Bioallied Sci. 2011;3(3):466-67. [DOI:10.4103/0975-7406.84471] [PMID] [PMCID]
7. Quinzii CM, Hirano M. Primary and secondary CoQ(10) deficiencies in humans. Biofactors. 2011;37(5):361-65. [DOI:10.1002/biof.155] [PMID] [PMCID]
8. Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Coenzyme Q10 supplementation in aging and disease. Front Physiol. 2018;9:44. [DOI:10.3389/fphys.2018.00044] [PMID] [PMCID]
9. Mantle D, Heaton RA, Hargreaves IP. Coenzyme Q10 and immune function: An overview. Antioxidants (Basel). 2021;10(5):759. [DOI:10.3390/antiox10050759] [PMID] [PMCID]
10. Sarmiento A, Diaz-Castro J, Pulido-Moran M, Kajarabille N, Guisado R, Ochoa JJ. Coenzyme Q10 supplementation and exercise in healthy humans: A systematic review. Curr Drug Metab. 2016;17(4):345-58. [DOI:10.2174/1389200216666151103115654] [PMID]
11. Tanrikulu AC, Abakay A, Evliyaoglu O, Palanci Y. Coenzyme Q10, copper, zinc, and lipid peroxidation levels in serum of patients with chronic obstructive pulmonary Disease. Biol Trace Elem Res. 2011;143: 659-67. [DOI:10.1007/s12011-010-8897-5] [PMID]
12. Gvozdjáková A, Kucharská J, Bartkovjaková M, Gazdíková K, Gazdík FE. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 2005;25:235-40 [DOI:10.1002/biof.5520250129] [PMID]
13. Marinari S, Manigrasso MR, De Benedetto F. Effects of nutraceutical diet integration, with coenzyme Q10 (Q-Termulticomposite) and creatine, on dyspnea, exercise tolerance, and quality of life in COPD patients with chronic respiratory failure. Multidiscip Respir Med. 2013;8(1):40. [DOI:10.1186/2049-6958-8-40] [PMID] [PMCID]
14. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65(10):930-6. [DOI:10.1136/thx.2009.130260] [PMID]
15. Zozina V, Covantev S , Kukes G , Corlateanu A. Coenzyme Q10 in COPD: An unexplored opportunity? COPD. 2021;18(1): 114-22. [DOI:10.1080/15412555.2020.1849084] [PMID]
16. Franssen FME, Smid DE, Deeg DJH, et al.The physical, mental, and social impact of COPD in a population-based sample:results from the Longitudinal Aging Study Amsterdam. NPJ Prim Care Respir Med.2018;28(1):30. [DOI:10.1038/s41533-018-0097-3] [PMID] [PMCID]
17. Vogiatzis I, Zakynthinos G, Andrianopoulos V. Mechanisms of physical activity limitation in chronic lung diseases. Pulm Med. 2012;2012:634761. [DOI:10.1155/2012/634761] [PMID] [PMCID]
18. Zhang HL, Li JS, Yu XQ, et al. An evaluation of activity tolerance, patient-reported outcomes and satisfaction with the effectiveness of pulmonary daoyin on patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:2333-2342. [DOI:10.2147/COPD.S117461] [PMID] [PMCID]
19. Mete B, Pehlivan E, Gülbaş G, Günen H. Prevalence of malnutrition in COPD and its relationship with the parameters related to disease severity. Int J Chron Obstruct Pulmon Dis. 2018;13:3307-12. [DOI:10.2147/COPD.S179609] [PMID] [PMCID]
20. Porter DA, Costill DL, Zachwieja JJ,et al. The effect of oral coenzyme Q10 on the exercise tolerance of middle-aged, untrained men. Int J Sports Med. 1995;16(7):421-7. [DOI:10.1055/s-2007-973031] [PMID]
21. Cooke M, Iosia M, Buford T, et al. Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. J IntSoc Sports Nutr. 2008;5:8. [DOI:10.1186/1550-2783-5-8] [PMID] [PMCID]
22. Marinari S, Manigrasso MR, De Benedetto F. Effects of nutraceutical diet integration, with coenzyme Q10 (Q-Termulticomposite) and creatine, on dyspnea, exercise tolerance, and quality of life in COPD patients with chronic respiratory failure. MultidiscipRespir Med. 2013;8(1):40. [DOI:10.1186/2049-6958-8-40] [PMID] [PMCID]
23. Silva DR, Gazzana MB, Knorst MM. C-reactive protein levels in stable COPD patients: a casecontrol study. Int J Chron Obstruct Pulmon Dis. 2015;10:1719-1725. [DOI:10.2147/COPD.S87015] [PMID] [PMCID]
24. Aksu F, Capan N, Aksu K,et al . C-reactive protein levels are raised in stable chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure. J Thorac Dis. 2013;5(4):414-21.
25. Gutierrez-Mariscal FM, Arenas-de Larriva AP, Limia-Perez L, Romero-Cabrera JL, Yubero-Serrano EM, López-Miranda J. Coenzyme Q10 supplementation for the reduction of oxidative stress: Clinical implications in the treatment of chronic diseases. Int J Mol Sci. 2020;21(21):7870. [DOI:10.3390/ijms21217870] [PMID] [PMCID]
26. Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol. 2007;85(1):141-7. [DOI:10.1139/y06-093] [PMID]
27. Fallah M, Askari G, Soleimani A, Feizi A, Asemi Z. Clinical trial of the effects of coenzyme Q10 supplementation on biomarkers of inflammation and oxidative stress in diabetic hemodialysis patients. Int J Prev Med. 2019;10:12. [DOI:10.4103/ijpvm.IJPVM_418_18] [PMID] [PMCID]
28. Aslani Z, Shab-Bidar S, Fatahi S, Djafarian K. Effect of coenzyme Q10 supplementation on serum of high sensitivity c-reactive protein level in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Int J Prev Med. 2018;9:82. [DOI:10.4103/ijpvm.IJPVM_263_17] [PMID] [PMCID]
29. Fujimoto S, Kurihara N, Hirata K, Takeda T. Effects of coenzyme Q10 administration on pulmonary function and exercise performance in patients with chronic lung diseases. ClinInvestig. 1993;71(8 Suppl):S162-6. [DOI:10.1007/BF00226860] [PMID]
30. Comhair SA, Grandon D, Khan A, Zhang R, Hazen SL, Erzurum SC. Coenzyme Q in asthma. Am J Respir Crit Care Med. 2015;191(11):1336-38. [DOI:10.1164/rccm.201412-2259LE] [PMID] [PMCID]
31. Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2016;3(3):CD007435. [DOI:10.1002/14651858.CD007435.pub3]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
